You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 131 - 140 of 207699 results
  1. Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies

    SBC: DNASTAR, INC.            Topic: NIAID

    Therapeutic monoclonal antibodies bind to specific regions of proteins called epitopes, which elicit cellular responses that treat or cure disease. Discovering therapeutic antibodies traditionally requires costly and labor- intensive, laboratory-based screening experiments. Computational approaches that select antibodies with the most desirable pharmaceutical properties are thus poised to improve ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel therapeutic for HPA hyperactivity

    SBC: STRESS THERAPEUTICS, INC.            Topic: 350

    Summary.The hypothalamic pituitary adrenal (HPA) axis is the key neuroendocrine system that controls peripheral responses to stress. While the stress response is essential for survival, it can become dysregulated. Hyperactivity of the HPA characterizes a variety of illnesses including alcohol use disorder (AUD). HPA hyperactivity is characterized by higher production of corticotropin-releasing fac ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Regulatory clearance of the Glide Control Strategy for Upper Limb Prostheses

    SBC: INFINITE BIOMEDICAL TECHNOLOGIES, LLC            Topic: NICHD

    Regulatory clearance of the Glide Control Strategy for Upper Limb Prostheses ABSTRACT There is a pressing need to improve control of myoelectric prostheses for individuals with upper limb loss (ULL). To date, only two fundamental control methods have been made commercially available – Direct Control (DC, introduced in 1960) and Pattern Recognition (PR, introduced in 2016). Both have significant ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Non-surgical treatment option for pelvic organ prolapse

    SBC: REIA LLC            Topic: NICHD

    Project Summary / Abstract Reia is working to address a prevalent gynecological condition, pelvic organ prolapse (POP), which affects more than 50% of women over the age of 50. POP occurs when the pelvic floor connective tissue and muscles weaken, allowing the uterus or vaginal walls to descend. In extreme cases, the uterus descends through the opening of the vagina and hangs outside of the body. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-functional anti-thrombotic therapy for coronary microvascular obstruction

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong ABSTRACTAdjunctive antithrombotic treatment with dual antiplatelet therapy (aspirin + P2Y12 antagonist) plus anticoagulant (heparin or bivalirudin) is an established treatment regimen for percutaneous coronary intervention (PCI) patients. Despite aggressive antithrombotic therapy, myocardial perfusion after PCI remains inad ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959

    SBC: T3D Therapeutics, Inc.            Topic: NIA

    T3D-959 is a new chemical entity, orally delivered, small molecule, dual nuclear receptor agonist aimed at improving dysfunctional brain glucose energy and lipid metabolism in Alzheimer’s disease (AD), it is non- amyloid/non-tau-directed. Metabolic homeostasis, inherently altered in AD, leads to protein misfolding resulting in plaque formation, tangle formation and inflammation. Exploratory huma ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Therapeutic Device to Improve Speech Sound Differentiation in Preterm Infants

    SBC: Thrive Neuromedical, LLC            Topic: NIDCD

    PROJECT DESCRIPTION Thrive Neuromedical LLC proposes to develop, test, and gain FDA clearance to market a therapeutic device to improve speech sound differentiation in preterm infants hospitalized in the neonatal intensive care unit (NICU). During this project we will complete development of the smallTalk NICU Active system and conduct a clinical trial to prove its efficacy in improving speech sou ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control

    SBC: ABVACC, INC.            Topic: NIAID

    The ebolaviruses (EBOV, SUDV, BDBV) and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with very high mortality rates. The 2013-2016 Ebola virus disease (EVD) outbreak in West Africa highlighted the serious nature of a filovirus epidemic and its regional and global implications. This outbreak took an enormous toll on people at the front line of the epide ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Augmented Reality Platform for Telehealth Rehabilitation

    SBC: ALTEC, INC            Topic: NIA

    Restrictions imposed by the COVID-19 global pandemic have continued to alter the delivery of, and access to, healthcare across the nation. The resulting unmet health needs have had a disproportionate effect among older Americans as they continue to be at the highest mortality risk for the latest variants of COVID-19. Additional health disparities due to race, gender, residential location, and inco ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government